192 related articles for article (PubMed ID: 34311592)
21. Communities, Mistrust, and Implementation: Addressing a Large Gap in the National Strategy for COVID-19 and Future Pandemics.
Hu H; Gilliland F; Baezconde-Garbanati L
Am J Public Health; 2022 Dec; 112(12):1713-1715. PubMed ID: 36302214
[No Abstract] [Full Text] [Related]
22. Cost-Related Barriers and Ensuring Equitable Access to Vaccines in the US.
Essien UR; Dusetzina SB
JAMA Pediatr; 2023 Nov; 177(11):1117-1118. PubMed ID: 37669068
[TBL] [Abstract][Full Text] [Related]
23. Improving Equity, Diversity, and Inclusion in Plastic, Reconstructive, and Aesthetic Surgery in Canada: A Call to Action.
Snell L; Valiquette CR; Avery E; Moltaji S; Forrest CR
Plast Surg (Oakv); 2022 May; 30(2):94-101. PubMed ID: 35572078
[TBL] [Abstract][Full Text] [Related]
24. Applications of an Equity Framework in COVID-19 Vaccine Trial and Distribution Planning.
Davis A; Mendez DD
Health Equity; 2022; 6(1):55-58. PubMed ID: 35112047
[TBL] [Abstract][Full Text] [Related]
25. COVID-19 vaccine: Call for employees in international transportation industries and international travelers as the first priority in global distribution.
Yu Z; Wang G; Goldman E; Zangerl B; Xie N; Cao Y; Chen J; Day SW; Howard SC; Maida M; Ray K; Jablonski MM; Ji J; Postlethwaite A; Gu W; Sun D; Aleya L
Open Med (Wars); 2021; 16(1):134-138. PubMed ID: 33521319
[TBL] [Abstract][Full Text] [Related]
26. Leveraging preclinical study designs to close gaps in vaccine development for perinatal pathogens.
Crooks CM; Chan C; Permar SR
J Exp Med; 2023 Jul; 220(7):. PubMed ID: 37289272
[TBL] [Abstract][Full Text] [Related]
27. Editorial: Vaccines and immunization services during the pandemic era and beyond.
Amponsah-Dacosta E; Fulurija A; Afum-Adjei Awuah A; Mathema S; Wariri O
Front Health Serv; 2024; 4():1394381. PubMed ID: 38550921
[No Abstract] [Full Text] [Related]
28. Correction to: Retrospective analysis of equity-based optimization for COVID-19 vaccine allocation.
PNAS Nexus; 2023 Oct; 2(10):pgad323. PubMed ID: 37811339
[TBL] [Abstract][Full Text] [Related]
29. From Lessons to Enduring Legacies: Building Upon COVID-19 Health Equity Science.
Fenton KA
Public Health Rep; 2024; 139(3):284-287. PubMed ID: 38459795
[No Abstract] [Full Text] [Related]
30. Reporting of health equity considerations in vaccine trials for COVID-19: comment.
Daungsupawong H; Wiwanitkit V
J Clin Epidemiol; 2024 Mar; ():111329. PubMed ID: 38521365
[No Abstract] [Full Text] [Related]
31. Response to "Reporting of health equity considerations in vaccine trials for COVID-19: comment".
Kou R; Mbuagbaw L
J Clin Epidemiol; 2024 Apr; ():111374. PubMed ID: 38697405
[No Abstract] [Full Text] [Related]
32. Building a pandemic supply chain - equity over equality.
Yee V; Bajaj SS; Stanford FC
Nat Med; 2022 Apr; 28(4):609-610. PubMed ID: 35288699
[No Abstract] [Full Text] [Related]
33. Integrated early years data system associated with pro-equity impact through COVID.
Shanahan K; Jelleyman T
J Paediatr Child Health; 2024; 60(2-3):76-77. PubMed ID: 38324612
[No Abstract] [Full Text] [Related]
34. Research with Marginalized Communities: Challenges to Continuity During the COVID-19 Pandemic.
Sevelius JM; Gutierrez-Mock L; Zamudio-Haas S; McCree B; Ngo A; Jackson A; Clynes C; Venegas L; Salinas A; Herrera C; Stein E; Operario D; Gamarel K
AIDS Behav; 2020 Jul; 24(7):2009-2012. PubMed ID: 32415617
[No Abstract] [Full Text] [Related]
35. Preparing the Community for a Vaccine Against COVID-19.
Al Awaidy ST; Khamis F
Oman Med J; 2020 Nov; 35(6):e193. PubMed ID: 33110636
[No Abstract] [Full Text] [Related]
36. Bold moves for vaccine manufacturing equity.
Aars OK; Schwalbe N
Lancet; 2023 Sep; 402(10404):771-772. PubMed ID: 37659773
[No Abstract] [Full Text] [Related]
37. Vaccines need equity to really work.
The Lancet Microbe
Lancet Microbe; 2022 Dec; 3(12):e888. PubMed ID: 36462523
[No Abstract] [Full Text] [Related]
38. COVID-19 vaccine equity and booster doses.
The Lancet Infectious Diseases
Lancet Infect Dis; 2021 Sep; 21(9):1193. PubMed ID: 34391506
[No Abstract] [Full Text] [Related]
39. COVID-19 vaccine equity: a health systems and policy perspective.
Van De Pas R; Widdowson MA; Ravinetto R; N Srinivas P; Ochoa TJ; Fofana TO; Van Damme W
Expert Rev Vaccines; 2022 Jan; 21(1):25-36. PubMed ID: 34758678
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Walter EB; Talaat KR; Sabharwal C; Gurtman A; Lockhart S; Paulsen GC; Barnett ED; Muñoz FM; Maldonado Y; Pahud BA; Domachowske JB; Simões EAF; Sarwar UN; Kitchin N; Cunliffe L; Rojo P; Kuchar E; Rämet M; Munjal I; Perez JL; Frenck RW; Lagkadinou E; Swanson KA; Ma H; Xu X; Koury K; Mather S; Belanger TJ; Cooper D; Türeci Ö; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
N Engl J Med; 2022 Jan; 386(1):35-46. PubMed ID: 34752019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
